Author

A. M. Gilligan

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study.

BACKGROUND Folate receptor alpha (FRα) is overexpressed in most high-grade ovarian cancers (HGOC), but use of the FRα-targeting drug mirvetuximab soravtansine-gynx (MIRV) is limited by expression-level restrictions and toxicity profile. Sofetabart mipitecan (Sofe-M) is a novel FRα-targeting antibody-drug conjugate desi...

I. Ray-Coquard, D. O'Malley, A. Oaknin et al. · Annals of Oncology · 0 citations

Review Open access Oct 2026

Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.

PURPOSE Selpercatinib, a highly selective oral RET inhibitor with CNS activity, has previously demonstrated durable responses and an acceptable safety profile in adults with RET-driven cancers. Consequently, the safety and efficacy of selpercatinib were investigated in pediatric/adolescent participants. METHODS LIBRE...

T. Laetsch, H. Kang, M. Casanova et al. · Journal of Clinical Oncology · 0 citations

Sep 2026

Oncology Patients in Clinical Trials: A Health Care Cost Analysis.

OBJECTIVES To assess health care resource utilization and costs among commercially insured patients with colorectal cancer (CRC) or ovarian cancer (OC) participating in clinical trials (PCTs). STUDY DESIGN A retrospective claims analysis from 2017 to 2022 was conducted using the Milliman Consolidated Health Cost Guid...

Christine Ferro, Kate Fitch, Prachi D. Bhatt et al. · American Journal of Managed... · 0 citations